Aptose Biosciences is a clinical-stage biotechnology company developing differentiated therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research. The company's pipeline includes small molecules designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
Company Profile
Latest Presentation
Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
View This PresentationIndustry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical and Medicine Industry (3741)
Contact Information
Investor Relations
ir@aptose.com
Company Contact
Aptose Biosciences Inc.
66 Wellington Street West
Suite 5300
TD Bank Tower Box 48
Toronto, ON M5K 1E6
Canada
T: 858.926.2730